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ABSTRACT
Gastrin-releasing peptide receptor (GRPR), a
member of the G protein-coupled receptor super-
family, has been utilized for receptor-mediated tar-
geting of imaging and therapeutic agents; here we
extend its use to oligonucleotide delivery. A
splice-shifting antisense oligonucleotide was
conjugated to a bombesin (BBN) peptide, and its
intracellular delivery was tested in GRPR expressing
PC3 cells stably transfected with a luciferase gene
interrupted by an abnormally spliced intron. The
BBN-conjugate produced significantly higher
luciferase expression compared to unmodified
oligonucleotide, and this increase was reversed by
excess BBN peptide. Kinetic studies revealed a
combination of saturable, receptor-mediated endo-
cytosis and non-saturable pinocytosis for uptake of
the conjugate. The Km value for saturable uptake
was similar to the EC50 value for the pharmacol-
ogical response, indicating that receptor-mediated
endocytosis was a primary contributor to the
response. Use of pharmacological and molecular
inhibitors of endocytosis showed that the conjugate
utilized a clathrin-, actin- and dynamin-dependent
pathway to enter PC3 cells. The BBN-conjugate
partially localized in endomembrane vesicles that
were associated with Rab7 or Rab9, demonstrating
that it was transported to late endosomes and the
trans-golgi network. These observations suggest
that the BBN-oligonucleotide conjugate enters
cells via a process of GRPR mediated endocytosis
followed by trafficking to deep endomembrane
compartments.
INTRODUCTION
Oligonucleotide-based therapeutics has shown promise for
treating a variety of diseases. New generations of antisense
oligonucleotides provide better biological and pharma-
ceutical properties than conventional phosphorothioate
oligonucleotides (1–4). Additionally, the discovery of
mammalian RNA interference (RNAi) has enabled a
new strategy for therapeutic regulation of gene expression
(5,6). Promising results for both antisense and RNAi have
been attained in cell culture and animal models, and this
has driven the initiation of clinical trials. As of 2008, 17
US pharmaceutical industry sponsored clinical trials were
ongoing with therapeutic oligonucleotides (http://www
.phrma.org/). Despite these exciting prospects, a key
hurdle impeding the wider success of this approach is
poor delivery of oligonucleotides to their functional sites
within cells, due to the need to cross several biological
barriers subsequent to administration (7,8).
There are two major strategies to overcome biological
barriers and allow successful delivery. One is to formulate
oligonucleotides into nanoparticles with cationic lipids or
polymers in order to improve intracellular uptake and
endosomal release. This strategy has achieved signiﬁcant
success in cellular and animal studies (9–12); however, the
large size and/or considerable toxicity of cationic lipid and
polymer complexes may raise issues for clinical utilization
(13). Another strategy is to utilize receptor-mediated tar-
geting for pharmacologically eﬀective delivery of antisense
and siRNA oligonucleotides, in which a ligand that select-
ively binds to a cell surface receptor is chemically
conjugated to the oligonucleotide (14). The potential ad-
vantages of this strategy are: (i) it will allow preferential
delivery of the ligand–oligonucleotide conjugate to par-
ticular tissues and cell types in which the targeted
receptor is diﬀerentially expressed; (ii) it may deliver the
oligonucleotide to appropriate sites of action within cells;
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will allow ready egress from the blood and widespread
distribution in tissues, which may be a signiﬁcant advan-
tage over various particulate oligonucleotide carriers in
terms of in vivo pharmacokinetics, biodistribution and
therapeutic eﬀect.
Members of the integrin family of cell surface receptors
have been utilized to deliver oligonucleotide conjugates
(15,16), but evaluating additional types of receptors may
contribute to the ultimate success of this approach (17).
The G protein-coupled receptors (GPCRs) comprise the
largest receptor family in the human genome with  850
members (18). The conformational changes of GPCRs
upon ligand occupancy lead to the dissociation of the
a- and b/g-subunits of the coupled G protein, thus trig-
gering downstream eﬀectors to produce changes in cell
function, such as alteration of cAMP levels, activation
of ion channels and activation of phospholipases (19).
Regulation of the signaling activity of GPCRs involves
processes of receptor internalization and recycling, which
occur primarily through clathrin-mediated endocytosis
(20). Once internalized, GPCRs can be sorted into
various traﬃcking pathways including recycling to the
cell surface, or degradation in lysosomes (21,22). Since
clathrin mediated endocytosis is usually considered to be
a high capacity pathway (23), this suggests that GPCRs
may be suitable vehicles for eﬃcient intracellular delivery
of ligand–oligonucleotide conjugates.
Within GPCRs, bombesin (BBN) family receptors have
been successfully used for receptor-mediated delivery of
cytotoxins, immunotoxins and radioactive compounds
(24,25). This family is composed of the neuromedin B
receptor (NMBR) and gastrin-releasing peptide receptor
(GRPR) sub-families (26). Over-expression of GRPRs has
been implicated in breast, prostate, small cell lung, and
pancreatic cancers (27). This has led to a substantial
amount of work using BBN analogs to selectively deliver
both imaging agents and conventional cytotoxic drugs to
tumors (27,28). In the current study, this approach has
been extended to delivery of oligonucleotides. The BBN
peptide was coupled to a ‘splice-shifting oligonucleotide’
(SSO) designed to correct splicing of an aberrant intron
inserted into the ﬁreﬂy luciferase reporter gene. Thus, suc-
cessful delivery of the SSO to the cell nucleus would result
in up-regulation of luciferase activity. This study showed
that the BBN peptide can eﬀectively deliver the SSO to
GRPR positive cells in culture via a receptor-mediated
endocytotic process. Preliminary mechanistic studies also
delineated the endocytotic and intracellular traﬃcking
pathways that may contribute to the eﬀectiveness of the
BBN–oligonucleotide conjugate.
MATERIALS AND METHODS
Synthesis and chemical characterization of
peptide-oligonucleotide conjugates
The 20-O-Me phosphorothioate oligonucleotide 623 (50GT
TATTCTTTAGAATGGTGC30), its 30-Tamra conjugate
and 50-thiol oligonucleotide, as well as the mismatched
control (50GTAATTATTTATAATCGTCC30), were
prepared as previously reported (15). In brief, oligonucleo-
tides were synthesized using phosphoramidites of the
ultraMILD-protected bases on 30-Tamra CPG supports
(Glen Research, Sterling, VA, USA) using a AB 3400
DNA synthesizer (Applied Biosystems, Foster City, CA,
USA). To prepare peptide conjugates, a thiol linker was
introduced at the 50-end of the oligonucleotides. After
cleavage from the CPG support and deprotection, the
oligonucleotides were puriﬁed by reverse-phase HPLC
on a Varian HPLC system (ProStar/Dynamax, Walnut
Creek, CA, USA) and identiﬁed using matrix-assisted
laser desorption ionization time-of-ﬂight (MALDI–TOF)
mass spectroscopy on a Voyager Applied Biosystem in-
strument (Foster City). The peptide BBN(6–14) was
reacted with maleimide NHS ester in borate buﬀer at
room temperature. Then, BBN–maleimide was isolated
by semi-preparative HPLC and conﬁrmed by MALDI–
TOF. Thiol oligonucleotides were reacted with the
maleimide-containing BBN peptide in a reaction buﬀer
(ﬁnal salt concentration adjusted to 400mM KCl, 40%
aqueous CH3CN). The reaction mixture was vortexed
and allowed to stand for 3h, and puriﬁed by HPLC
using a 1ml Resource Q column (GE Healthcare,
Uppsala, Sweden). The puriﬁed conjugates were dialyzed
versus milli-Q water, and analyzed by MALDI–TOF.
Cell lines, plasmids and transfection
PC3 prostate cancer cells were cultured in F12K medium
(Gibco/Invitrogen, Carlsbad, CA, USA) supplemented
with 10% fetal bovine serum (FBS). The plasmid pLuc/
705, containing an aberrant intron inserted into the ﬁreﬂy
luciferase coding sequence was a kind gift from Dr R.
Kole (University of North Carolina) (29). The Luc705
cassette was ampliﬁed from the plasmid pLuc/705 using
the forward primer 50TGCATGCTCGAGACATTTTAC
AATTTGG30 and reverse primer 50CCTGCAGGCATGC
AAGCTTGGCATTCCG30. Ampliﬁed PCR product was
inserted at the XhoI and HindIII site of pcDNA3.1/hygro
(Invitrogen) resulting in the plasmid pcDNA3.1/hygro/
Luc705. Stable transfectants were obtained by transfecting
PC3 cells with pcDNA3.1/hygro/Luc705 using
Lipofectamine 2000 as per manufacturer’s instructions.
Selection was carried out in F12K medium containing
200mg/ml hygromycin B (Roche) and 10% FBS for
2 weeks. Individual clones were picked and screened for
luciferase induction by 623 oligonucleotide complexed
with Lipofectamine 2000. The single cell clone with the
highest expression induced by 623 oligonucleotide was
referred to as PC3/Luc705 and used in further studies.
A dynamin dominant negative (DN) expression plasmid
was a kind gift from Dr JoAnn Trejo (University of
California at San Diego, USA). The plasmids encoding
eGFP-Rab5, eGFP-Rab7, eGFP-Rab9 and eGFP-Rab11
were kindly provided by Dr Stephen Ferguson (Robarts
Research Institute, Canada), Prof. Bo van Deurs
(University of Copenhagen, Denmark), Dr Suzanne
Pfeﬀer (Stanford University, USA) and Dr Martin
Alexander Schwartz (University of Virginia, USA), re-
spectively. Plasmids expressing eGFP chimeras of
dynamin or Rabs were transfected into the PC3/Luc705
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were transfected with plasmids under serum free condi-
tions in OPTI-MEM using Lipofectamine2000 as per
manufacturer’s instructions. Fourhours later media was
replaced with F12K supplemented with 10% FBS. The
following day cells were treated with oligonucleotides,
and uptake and intracellular distribution of the oligo-
nucleotides were analyzed by ﬂow cytometry and
confocal microscopy, respectively.
Cellular uptake by ﬂow cytometry
Total cellular uptake of the Tamra-labeled oligonucleotide
was measured by ﬂow cytometry using a LSR II cell
analyzer (Becton-Dickenson, San Jose, CA, USA). After
treatment with oligonucleotides for various times, the cells
were trypsinized and analyzed by ﬂow cytometry, with a
561nm laser and a 582/15 emission ﬁlters for Tamra ﬂuor-
escence, a 594nm laser and a 610/20 emission ﬁlters
for Alexa-594 ﬂuorescence, and a 488nm laser and a
525/50 ﬁlters for eGFP. For kinetic studies, varying
amounts of the Tamra-labeled oligonucleotide were
added to the culture medium to give increasing total
substrate concentrations. Uptake was determined in the
PC3/Luc705 cells over a 4-h period, which is within the
linear uptake region. Kinetic constants (Jmax, Km and Kd)
were obtained by ﬁtting a model incorporating saturable
and non-saturable components to the uptake data. The
following model was utilized:
J ¼
Jmax   C
Km+C
+Kd   C ð1Þ
where Jmax is the maximal uptake rate, Km is the kinetic
constant for saturable uptake, Kd is the kinetic constant
for non-saturable uptake, and C is the oligonucleotide
concentration. For inhibition studies, PC3/Luc705 cells
were ﬁrst treated with inhibitors for 30min, and then the
uptake of the conjugate was determined over a 4-h period
in the presence of inhibitors. Alexa-594 labeled transferrin
(Molecular Probes, Beaverton, OR, USA) was used as a
control for clathrin-mediated endocytosis. After pretreat-
ment with inhibitors in serum-free media, the cells were
treated with 20mg/ml transferrin for 15min in the presence
of the inhibitors, and then washed with acidic buﬀer to
remove external transferrin. Flow cytometry was utilized
to measure the uptake in both kinetic and inhibition
studies.
Oligonucleotide treatment and luciferase assay
PC3/Luc705 cells were plated on 24-well plates
(at 1.0 10
5 cells per well in various experiments) in
F12K supplemented with 10% FBS. The following day,
cells were treated with either free 623 oligonucleotide,
623 complexed with Lipofectamine 2000 as per manufac-
turer’s instruction, BBN–623 conjugate, or its mismatched
control prepared in OPTI-MEM I medium (Gibco). Four
hours after treatment, 1% FBS was added to each well.
Twenty-four hours after oligonucleotide treatment,
medium was replaced with F12K containing 1% FBS,
and at various times thereafter cell lysates were collected
for luciferase assay. Cells were usually harvested 48h after
oligonucleotide treatment, or at times indicated in the
ﬁgures. The expression of the ﬁreﬂy luciferase gene was
measured by real-time RT–PCR as described below and
the enzyme activity was determined using a Luciferase
assay kit (Promega, Madison, WI, USA). Luciferase
assay was performed on a FLUOstar Omega microplate
reader (BMG LABTECH, Cary, NC, USA). Protein
content was determined by the BCA protein assay
(Pierce, Rockford, IL, USA) with bovine serum albumin
as a standard. Background luciferase expression was
determined by measuring luciferase activity in the cells
without the oligonucleotide treatment, and these values
were then subtracted from the results in the treated cells
to obtain response values and the ﬁnal dynamic data. In
some cases, the eﬀects of the BBN–623 conjugate were
evaluated in the presence of free BBN peptide (Peptides
International Inc, Louisville, KY, USA).
For pharmacodynamic studies, varying amounts of the
BBN–623–Tamra were added to the culture medium to
give increasing total substrate concentrations. Luciferase
induction was determined in the PC3/Luc705 cells over a
24-h treatment followed by a 2-day culture.
Pharmacodynamic constants (Emax,E C 50 and g) were
obtained by ﬁtting a general sigmoid model to the induc-
tion data. The following model was utilized:
E ¼
Emax   C 
EC
 
50+C  ð2Þ
where E is the eﬀect observed at the oligonucleotide con-
centration C, Emax is the maximal response that can be
produced by the oligonucleotide, EC50 is the concentra-
tion of the drug that produces 50% of maximal eﬀect, and
g is the Hill coeﬃcient indicating the slope of the sigmoid
curve.
RNA extraction and real-time RT–PCR
Total RNA was isolated using an RNeasy Mini kit
(Qiagen Inc., Valencia, CA, USA), and cDNA was
synthesized from total RNA using an Enhanced Avian
First Strand Synthesis Kit (Sigma, St Louis, MO, USA).
The forward primer (50CGATCCCTTCAGGATTAC
AAA30), the reverse primer (50GAGTGCTTTTGGCGA
AGAAT30), and the TaqMan MGB probe (6FAM-TCA
AAGTGCGTTGCTAGTACCAACCC-MGBNFQ) were
designed based on ﬁreﬂy luciferase cDNA sequence using
Primer3 software and were synthesized by Applied
Biosystems (Foster City). The forward primer spans the
insertion site of the aberrant intron 705 so that only cor-
rectly spliced luciferase mRNA can be ampliﬁed in the
RT-PCR reaction. TaqMan

Human GAPDH Control
Reagents (Applied Biosystems) were used for quantiﬁca-
tion of GAPDH in each sample and served as an internal
control. Real-time PCR was performed using the ABI
PRISM 7900 sequence detection system (Applied
Biosystems). The luciferase expression levels of samples
were calculated with the Comparative CT Method
(CT Method) and were expressed as fold changes
over those of the non-treated cells.
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Intracellular distribution of the oligonucleotide in living
cells was examined using a Zeiss 510 Meta Inverted Laser
Scanning Confocal Microscope with 63 -oil immersion
objectives. PC3/Luc705 cells were plated in 35mm glass
bottom microwell dishes (MatTek, Ashland, MA, USA).
After transfection of dynamin DN plasmid, intracellular
uptake of the oligonucleotide, or of Alexa-594 labeled
transferrin (Molecular Probes) as a marker for
clathrin-coated vesicles, was visualized by confocal mi-
croscopy. Co-localization of the Tamra-labeled oligo-
nucleotide with Alexa-488 labeled transferrin (Molecular
Probes) was also done by confocal microscopy.
Sub-cellular localization of BBN–623–Tamra in speciﬁc
endomembrane compartments was performed by
co-localization of the oligonucleotide with eGFP-Rab5
(early endosome marker), eGFP-Rab7 (late endosome
marker), eGFP-Rab9 (trans-Golgi marker) and
eGFP-Rab11 (recycling endosome marker), respectively,
after expression of these plasmids in the cells.
Data analysis
Data are expressed as mean±SD from three measure-
ments unless otherwise noted. Statistical signiﬁcance was
evaluated using t-test or ANOVA followed by Dunnet’s
test for multiple comparisons. The data were analyzed
with GraphPad Prism 5 (GraphPad Software, Inc.,
La Jolla, CA, USA). Parameter estimates were obtained
by ﬁtting the model to the cellular uptake and luciferase
induction data using non-linear least-squares regression
(WinNonlin, Pharsight, Mountain View, CA, USA). A
weighting scheme of 1/Y and the Gauss–Newton
(Levenberg and Hartley) minimization method were
used for each modeling exercise.
RESULTS
Synthesis and characterization
The chemical structure of the ﬁnal oligonucleotide conju-
gate is shown in Figure 1A. A Tamra ﬂuorophore was
introduced at the 30-end of the oligonucleotide 623 or its
mismatched control (5MM623). The BBN peptide (6–14)
with maleimide functionality was coupled with the 50-thiol
oligonucleotides. After puriﬁcation by ion-exchange chro-
matography, the identity of the ﬁnal products were
conﬁrmed by MALDI–TOF mass spectroscopy (BBN–
623–Tamra: calculated mass=9129.3 (M+H)
+ and mass
found=9128.5 (M+H)
+; BBN-5MM623–Tamra:
calculated mass=9059.0 (M+H)
+ and mass
found=9059.6 (M+H)
+) (Figure 1B).
Cellular uptake and luciferase induction
The kinetics of total cellular uptake of 623–Tamra or its
BBN–conjugate was evaluated by incubating cells with
these molecules up to 24h and then measuring total
cell-associated ﬂuorescence by ﬂow cytometry. As seen
in Figure 2A, there was at least a 2-fold greater uptake
of the BBN–conjugate as compared to the unconjugated
oligonucleotide at each time point. To evaluate
pharmacological eﬀects, free 623, the BBN–623 conjugate,
the BBN-5MM623, and free 623 complexed with
Lipofectamine 2000 (all 50nM) were incubated with
PC3/Luc705 cells and the cells were tested for luciferase
expression by real-time RT–PCR (Figure 2B) and
luciferase enzyme assay (Figure 2C). As seen in
Figure 2B, the BBN–623 conjugate produced a signiﬁcant
increase in luciferase gene expression compared to the
unconjugated 623 at the same concentration. Treatment
of PC3/Luc705 cells with a mismatched oligonucleotide
conjugated with BBN peptide failed to produce an
increase in luciferase gene expression, indicating that the
luciferase response depends on speciﬁc interaction of
the 623 oligonucleotide with the splicing machinery in
the nucleus. As seen in Figure 2C, the result from the
luciferase assay conﬁrmed that the BBN–623 conjugate
generated a signiﬁcantly higher luciferase activity
compared to the free 623. To test whether the eﬀect of
the BBN–623 conjugate on splicing of the luciferase
reporter was due to receptor-mediated endocytosis
involving GRPR, excess amounts of full-length BBN
peptide, a ligand that binds to the same site on the
receptor, were used in the experiment. Co-incubation
with 10mM of this peptide led to full inhibition of the
eﬀect of the BBN–conjugate on luciferase expression
(Figure 2C). This observation supports the concept that
the eﬀect of the BBN–conjugate on splicing largely
depends on its initial uptake via GRPR. In addition,
neither 623–Tamra oligonucleotide nor its BBN–conju-
gate showed toxicity at concentrations up to 1000nM
since the protein content of the treated cells was the
same as the control when measured at the end of the in-
duction experiment.
Dose–response studies of cellular uptake and
biological eﬀect
Cell uptake and pharmacological response for the BBN–
conjugate were evaluated as a function of concentration.
The initial uptake rate of the conjugate (at 37 C for 4h) as
a function of concentration was well described by a model
consisting of one saturable and one non-saturable terms
(Figure 3A). The Jmax and Km estimated for the saturable
component were 2336±454 FU/4h and 122±32nM.
The non-saturable component of uptake, Kd, was
estimated to be 2.1±0.4FU/4h/nM. The Km value is
similar to the reported binding aﬃnity of BBN to the
GRPR, 79nM (30). The data are consistent with a com-
bination of a saturable, receptor-mediated endocytosis
and non-saturable pinocytosis accounting for uptake of
the conjugate in PC3 cells. The luciferase induction by
the conjugate as a function of concentration was also sat-
urable and well described by a general sigmoid model. The
Emax and EC50 estimated for the response were
440832±75734LUs/mg protein and 97±21nM, re-
spectively (Figure 3B). The EC50 value was similar to
the Km value for saturable uptake of the conjugate
(122±32nM), which suggests that saturable,
receptor-mediated endocytosis is the main contributor to
the eﬀectiveness of the conjugate.
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The time-dependent response of luciferase to the BBN–
623 conjugate was examined by harvesting the cells at
various times after the period of exposure to the oligo-
nucleotide. Figure 4 shows a striking diﬀerence between
the time proﬁles of the responses induced by the BBN–623
conjugate and a cationic lipid/623 complex. The cationic
lipid/623 was more eﬀective than the BBN–conjugate
showing a 2.6-fold higher AUC of the time-dependent
response curve up to 96h (Figure 4). The eﬀect of the
BBN–623 conjugate on luciferase expression rose gradual-
ly with time and reached a maximum at 72h (48h after
removal of the oligonucleotide). In contrast, the eﬀect of
the cationic lipid/623 complex peaked at early time points
after dosing and declined steadily thereafter. This diﬀer-
ence may result from the diﬀerent delivery mechanisms
utilized by the receptor targeted conjugate and the
cationic lipid complex. The oligonucleotide delivered via
cationic lipids seems to reach the nucleus rapidly possibly
due to quick endosomal release, while that delivered via
the peptide-conjugate seems to traﬃc through other intra-
cellular compartments and only gradually reach the
nucleus where the eﬀect on splicing takes place.
Uptake pathway
The eﬀects of some known endocytosis inhibitors on the
initial uptake rate of the BBN–conjugate were examined.
Chlorpromazine is thought to interfere selectively with
Figure 1. Chemical structure (A) and mass spectrum of the BBN–623 conjugate (B).
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blocks actin ﬁlament function, which is necessary for
most forms of endocytosis (31). Both cytochalasin D
(2mM) and chlorpromazine (10mM) inhibited the endo-
cytosis of transferrin, a well-known marker for
clathrin-mediated endocytosis (Figure 5); as well, both
agents reduced the uptake of the BBN–623 conjugate.
The inhibition studies supported the concept that the
Figure 2. Cellular uptake kinetics (A) and luciferase induction
measured by RT-PCR (B) and luciferase assay (C) for 623–Tamra
and BBN–623–Tamra. (A) Cells in 24-well plates were treated with
50nM of free 623–Tamra, or BBN–623–Tamra, for 0–24h in
OPTI-MEM at 37 C. The cells were rinsed in buﬀered saline solution
and then trypsinized. Total cellular uptake of the Tamra-labeled oligo-
nucleotide was measured by ﬂow cytometry using a LSR II cell
analyzer (Becton–Dickenson, San Jose, CA, USA). (B) Cells were
treated with 623–Tamra, BBN–623–Tamra conjugate, or its mis-
matched control for 24h, or with 623–Tamra complexed with
Lipofectamine2000 for 4h, as described in Materials and methods
section, and luciferase gene expression was determined by real-time
RT-PCR after 24h for the liposomal complex or 48h for the other
treatments. (C) Cells were treated with either 623–Tamra, BBN–623–
Tamra conjugate or BBN–623–Tamra in the presence of excess free
BBN peptide (fBBN) for 24h as described in ‘Materials and
Methods’ section, and luciferase activity was determined after 48h.
Results are the means and standard deviations of triplicate determin-
ations. *P<0.05; ***P<0.001.
Figure 3. Dose-dependent initial cellular uptake (A) and response (B)
for BBN–623–Tamra. A. Cells in 96-well plates were treated with
increasing concentrations of BBN–623–Tamra, for 4h in OPTI-MEM
at 37 C. Then, the cells were rinsed in buﬀered saline solution and then
trypsinized. Total cellular uptake of the Tamra-labeled oligonucleotide
was measured by ﬂow cytometry using a LSR II cell analyzer (Becton–
Dickenson). The dashed line indicates the saturable component of
uptake while the dotted line indicates non-saturable uptake. (B) Cells
were treated with BBN–623–Tamra as described in ‘Materials and
Methods’ section, and luciferase activity was determined after 48h.
Results are the means and standard deviations of triplicate
determinations.
Figure 4. Time-dependent response studies. Cells were treated with
either BBN–623–Tamra conjugate for 24h or 623–Tamra complexed
with Lipofectamine 2000 for 4h, as described in ‘Materials and
Methods’ section, and luciferase activity was determined at the times
indicated after dosing. White bars represent luciferase activity of 50nM
BBN–623–Tamra conjugate and black bars represent 50nM 623–Tamra
complexed with Lipofectamine 2000, all expressed as RLUs/mg
protein. Results are the means and standard deviations of triplicate
determinations.
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clathrin-coated pits. Similar studies were done with
methyl-b-cyclodextrin and amiloride that putatively
inhibit lipid-raft mediated endocytosis and
macropinocytosis, respectively. The lack of eﬀect sug-
gested that lipid-raft mediated vesicles are not involved
in uptake of BBN–623, nor is macropinocytosis.
However, since pharmacological inhibitors often have
multiple eﬀects we decided to further investigate the
uptake and traﬃcking pathway of the conjugate.
Dynamin is a small GTPase that plays a key role in
pinching oﬀ membrane vesicles and clathrin-dependent
endocytotic pathways depend on the action of dynamin
(32). The potential role of dynamin in oligonucleotide
uptake in this system was examined by transfecting cells
with plasmids coding for a chimeric protein comprised of
a DN form of dynamin linked to eGFP. These cells were
then treated with transferrin labeled with Alexa-594 or
BBN–623–Tamra and observed for the extent of uptake
and the subcellular distribution of the accumulated ﬂuor-
escent molecules. As seen in Figure 6A, expression of high
levels of DN-dynamin-eGFP almost completely blocked
the accumulation of transferrin in intracellular vesicles,
indicating that the function of dynamin is blocked in the
transfected cells. The expression of DN-dynamin-eGFP
also blocked the uptake of BBN–623–Tamra as observed
in the confocal images. Flow cytometry can give a more
quantitative assessment of the role of dynamin. After
transfection, PC3 cells showed heterogeneous expression
of mutant dynamin reﬂected by the pattern of eGFP ex-
pression in ﬂow. In Figure 6B, the population of cells
labeled in blue did not express DN-dynamin-eGFP and
showed the same level of eGFP ﬂuorescence as control
cells, while the population labeled in purple showed high
expression of DN-dynamin eGFP. Tamra ﬂuorescence
from the BBN–conjugate in the untransfected (blue)
population was 1161 ﬂuorescence units, while in the
transfected (purple) population it was 385, a reduction
of about 3-fold. This conﬁrms that the uptake pathway
for the BBN–623 oligonucleotide is dependent on
dynamin function.
Subcellular distribution
The colocalization of the BBN–623 conjugate with
Alexa-488 labeled transferrin, a marker for
clathrin-coated vesicle endocytosis, was examined in live
cells. After treatment for 2h, there was partial
co-localization of the BBN–conjugate with transferrin
(Figure 7A), suggesting the BBN–oligonucleotide conju-
gate initially enters cells via a clathrin-mediated endocytic
process that is shared by transferrin. To further pursue the
subcellular fate of the BBN–conjugate we examined its
distribution as compared to well-known markers for
several endomembrane compartments. Rab small
GTPases, members of the Ras superfamily, are localized
at distinct membrane vesicles and are responsible for
membrane vesicle formation, development and traﬃcking
(33). Rab5, which is mainly localized to early endosomes,
mediates endocytosis and endosome fusion (34). Rab11
mediates slow return of receptors to the plasma
membrane through recycling endosomes (35). The late
endosome-associated Rab7 mediates maturation of late
endosomes and their fusion with lysosomes (36), whereas
another late endosomal GTPase, Rab9, mediates
traﬃcking between late endosomes and the trans-golgi
network (TGN) (37). PC3 cells were transiently trans-
fected with eGFP chimeras of these four Rabs, and sub-
sequently the traﬃcking of the BBN–623–Tamra in live
cells was examined by confocal microscopy of live cells.
As shown in Figure 7B, after 4-h treatment, vesicles con-
taining the conjugate were observed to colocalize with
Rab7 or Rab9, indicating that BBN–623 was transported
to late endosomes and the TGN. However, colocalization
was not observed between the BBN–conjugate and Rab5
or Rab11 containing vesicles at both early and late time
points (1 and 4h) (data not shown). 3D reconstructions of
the subcellular distribution of BBN–623 and the
eGFP-Rab proteins are shown in Supplementary
Figure S1, conﬁrming the intracellular localization of the
moieties displaying co-localization of the Rabs and
oligonucleotides.
DISCUSSION
Targeting GPCRs shows promise for receptor mediated
delivery of oligonucleotides. The GPCRs comprise the
largest receptor family in the human genome (18).
Individual members of this family often display diﬀeren-
tial expression in various tissues or between tumor and
normal tissue (25,38,39). Therefore, ligand–oligonucleo-
tide conjugates that bind a speciﬁc GPCR member can
potentially lead to targeted delivery to a particular
tissue. In addition, internalization and recycling of
GPCRs occurs primarily through clathrin mediated endo-
cytosis (20), which is usually considered to be a high
capacity pathway (23). This suggests that GPCRs may
be suitable vehicles for eﬃcient intracellular delivery of
Figure 5. Eﬀects of inhibitors on initial uptake of BBN–623–Tamra.
Cells were treated with endocytosis inhibitors at the indicated concen-
trations for 30min and then 20mg/ml Alexa594-transferrin or 50nM
BBN–623–Tamra was added. After 15min (transferrin) or 4h (BBN–
623–Tamra), the cells were rinsed in buﬀered saline solution and then
trypsinized. Total cellular uptake was measured by ﬂow cytometry
using a LSR II cell analyzer (Becton–Dickenson). Results represent
means and standard deviations of triplicate determinations and are
normalized based on cells receiving no inhibitor as 100%. **P<0.01;
***P<0.001.
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related growth factor receptor whose expression has
been detected in a large spectrum of human cancers,
with high levels found in prostate, gastrinoma, breast
and ovarian tumors (27). Thus, it has been considered
as a promising target for therapeutic interventions and
tumor detection. GRPR ligands have been extensively
utilized to target cytotoxins, immunotoxins and radio-
active compounds, and several of them have achieved
clinical success. Several studies have shown that
radiolabeled BBN peptides are suitable for detecting
GRPR-positive prostate cancer in vivo with PET
imaging (40–42). A BBN-derived, 99mTc-labeled
pentadecapeptide showed signiﬁcant uptake in tumor
tissues, including breast cancer and prostate cancer,
in pilot clinical studies (43). BBN analogs have also
been linked to several cytotoxic agents for delivering
these small molecule drugs in cancer treatment. AN-215,
a conjugate of 2-pyrrolinodoxorubicin and BBN peptide,
has been studied for almost a decade in many types of
cancer, and been recently used as single and combined
therapy in experimental ovarian cancers (44). In
addition, conjugation of paclitaxel with BBN peptide
enhanced cytotoxicity against human non-small-cell lung
cancer compared with unconjugated taxol (45).
In the current study, a splicing switching oligonucleotide
was conjugated to a BBN peptide. This conjugate showed
higher cellular uptake in GRPR expressing cells, and intra-
cellular delivery of this conjugate also produced an
enhanced pharmacological response in terms of splicing
correction, which was abolished by the presence of excess
BBN peptide. For the ﬁrst time, this study showed that
targeting GRPR also can be utilized for selective intracel-
lular delivery of oligonucleotides.
Use of selective endocytosis inhibitors and transfection
with a DN mutant dynamin showed that the BBN–623
conjugate utilized a clathrin-dependent, actin-dependent
and dynamin-dependent pathway to enter PC3 cells.
Accordingly, modeling of the dose-dependent uptake
data for BBN–623 revealed a combination of a major sat-
urable component, likely receptor-mediated endocytosis
and a minor non-saturable component, likely ﬂuid phase
pinocytosis, for uptake of the conjugate. In addition, the
Km value for saturable uptake of the conjugate was
quite similar to the EC50 value for the pharmacological
response. The pharmacodynamics of a splice switching
oligonucleotide is complicated even in a cell-based
model. The dose–response relationship depends on the
cellular uptake, intracellular traﬃcking to nucleus, and
the interaction of the oligonucleotide with the splicing
machinery the nucleus. However, the similarity of the
Km value for saturable uptake of the conjugate and
the EC50 value for the pharmacological response favors
the notion that it is the saturable, receptor-mediated com-
ponent of endocytosis that mainly contributes to the
eﬀectiveness of the conjugate.
Initial uptake of oligonucleotides is followed by sequen-
tial intracellular traﬃcking into a variety of endo-
membrane compartments. Intracellular traﬃcking can be
rate-limiting because non-productive pathways can cir-
cumvent the transport of oligonucleotides to the target;
for example, sorting to lysosomal vesicles may lead to
Figure 6. Eﬀects of DN dynamin on cellular uptake of BBN–623–Tamra. The potential role of dynamin in BBN–623–Tamra uptake was examined
by transfecting PC3 cells with a plasmid coding for DN-dynamin-eGFP. These cells were then treated with transferrin-Alexa-594 (20mg/ml) or the
BBN–623–Tamra conjugate (50nM) and observed by confocal microscopy for the extent and subcellular distribution of the accumulated ﬂuorescent
molecules. Additionally total cell uptake was quantitated by ﬂow cytometry. In (A) cells expressing high levels of DN-dynamin-eGFP are marked
with white arrows while untransfected or poorly transfected cells are marked with blue arrows. As seen, expression of high levels of
DN-dynamin-eGFP almost completely blocked the accumulation of transferrin in intracellular vesicles, indicating that the DN-dynamin-eGFP
construct is functional. The expression of DN-dynamin-eGFP also blocked the uptake of BBN–623–Tamra, as seen in the confocal images, and
also in the results from the ﬂow cytometry (Figure 6B). There an approximate 3-fold reduction in total uptake was observed at high levels of
eGFP-DN dynamin (purple dots) versus untransfected cells (blue dots). In (B) the abscissa is the expression of DN-dynamin-eGFP while the ordinate
is uptake of BBN–623–Tamra.
6574 Nucleic Acids Research, 2010,Vol.38, No. 19degradation. In this study, we observed that the BBN–623
conjugate was partially transported to late endosomes and
to the TGN. This route may represent a productive
pathway because it may bypass lysosomal degradation.
However, the current data cannot delineate a complete
picture of the traﬃcking from the TGN to the nucleus.
The relatively slow action of the conjugate in inducing
luciferase suggests that entry into the nucleus may occur
at a slow rate. In conclusion, this study has generated a
novel construct for intracellular delivery of oligonucleo-
tides via GPCR-mediated endocytosis, and has made an
initial examination of the endocytosis and intracellular
traﬃcking pathways that may contribute to the eﬀective-
ness of this construct.
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Supplementary Data are available at NAR Online.
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